SIREN : 845292416
DOPHARMA FRANCE is a French company founded 7 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in VAIR-SUR-LOIRE (44150), this company of category PME shows in 2024 a revenue of 30.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 30 404 649 € | 25 433 342 € | 25 937 269 € | 25 769 223 € | 22 064 678 € | 17 513 881 € |
| Net income | 789 423 € | -1 366 316 € | -1 745 062 € | -1 540 251 € | -4 102 616 € | -3 655 293 € |
| EBITDA | 2 570 439 € | 735 587 € | -1 108 279 € | -809 633 € | -4 407 093 € | -5 796 024 € |
| Net margin | 2.6% | -5.4% | -6.7% | -6.0% | -18.6% | -20.9% |
In 2024, DOPHARMA FRANCE achieves revenue of 30.4 M€. Over the period 2019-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +11.7%. Vs 2023, growth of +20% (25.4 M€ -> 30.4 M€). After deducting consumption (15.5 M€), gross margin stands at 14.9 M€, i.e. a rate of 49%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 2.6 M€, representing 8.5% of revenue. Positive scissor effect: EBITDA margin improves by +5.6 pts, sign of improved operational efficiency. This level of operating margin is satisfactory for the sector. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 789 k€, i.e. 2.6% of revenue. This profit can be retained or distributed to shareholders.
30 404 649 €
14 892 406 €
2 570 439 €
1 480 990 €
789 423 €
8.5%
The debt ratio (= Financial debt / Equity x 100) stands at 132%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 28%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 5.6 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 5.8% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. Satisfactory level allowing partial financing of growth.
131.631%
28.267%
5.842%
5.629
74.0%
In 2024, the debt ratio of DOPHARMA FRANCE (131.63) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of DOPHARMA FRANCE (28.3%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of DOPHARMA FRANCE (5.63) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
The liquidity ratio (= Current assets / Current liabilities) stands at 200.66. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 27.9x. Operating income very largely covers interest expenses: high safety margin.
200.655
27.91
In 2024, the liquidity ratio of DOPHARMA FRANCE (200.66) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of DOPHARMA FRANCE (27.9x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 35 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 43 days. Favorable situation: supplier credit is longer than customer credit by 8 days. Inventory turnover is 120 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 102 days of revenue, i.e. 8.6 M€ to permanently finance. Notable WCR improvement over the period (-25%), freeing up cash.
8 582 016 €
35 j
43 j
120 j
102 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 157 505€ to 484 109€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare DOPHARMA FRANCE with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of DOPHARMA FRANCE in 2024 is 30.4 M€.
Yes, DOPHARMA FRANCE generated a net profit of 789 k€ in 2024.
The headquarters of DOPHARMA FRANCE is located in VAIR-SUR-LOIRE (44150), in the department Loire-Atlantique.
The tax return of DOPHARMA FRANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
DOPHARMA FRANCE operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.